Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents

Trial Profile

Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
  • Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
  • Focus Therapeutic Use
  • Acronyms HPV-040 PRI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top